DEXWireNews

$ZYNE Plenty of time to get into Zynerba Pharma

Long
NASDAQ:ZYNE   None
Don't worry that you missed out on this initial move in the price, still plenty of room to run for ZYNERBA PHARMA, which specializes in the development and commercialism of cannabis treatments for conditions ranging from Epilepsy and Osteoarthritis. Although the stock has had a considerable move this month, it is still a low cap company with huge potential, so maybe no need to rush in but it is a long term investment, with a small allocation of capital for us.

⭐⭐⭐ Sign Up for Free ⭐⭐⭐

1) Download our Mobile App >>

Android: dexwirenews.com/APP

Apple: dexwirenews.com/iOS

2) Join our Telegram >> t.me/DEXWireNews

3) Follow @DEXWireNews on Social Media
Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.